The American Journal of Psychiatry

American Journal of Psychiatry  
Discipline Psychiatry
Language English
Edited by Robert Freedman
Publication details
Former name(s)
 American Journal of Insanity
Publication history
 1844–present
Publisher
Frequency Monthly
13.391
Standard abbreviations
Am. J. Psychiatry
Indexing
CODEN AJPSAO
ISSN 0002-953X (print)
1535-7228 (web)
LCCN 22024537
OCLC no. 1480183
Links

The American Journal of Psychiatry is a monthly peer-reviewed medical journal covering all aspects of psychiatry and the official journal of the American Psychiatric Association.[1] The first volume was issued in 1844, at which time it was known as the American Journal of Insanity. The title changed to the current form with the July issue of 1921.

According to the Journal Citation Reports, the journal has a 2017 impact factor of 13.391.[1]

Ethical concerns

Several complaints, including legal cases, have charged the American Journal of Psychiatry with being complicit in pharmaceutical industry corruption of clinical trial results.[2] In a Department of Justice case against Forest Pharmaceuticals, Forest pleaded guilty to the charges of misbranding the drug Celexa (citalopram).[3] The Complaint in Intervention clearly identifies a 2004 ghostwritten article published in the American Journal of Psychiatry in the names of Wagner et al[4] as a part of this illegal marketing of Celexa for pediatric depression.[5]

See also

References

  1. 1 2 "About The American Journal of Psychiatry". American Psychiatric Association. 2016. Retrieved 2016-05-07.
  2. ↑ The citalopram CIT-MD-18 pediatric depression trial: Deconstruction of medical ghostwriting, data mischaracterisation and academic malfeasance' by Jureidini, Jon, Amsterdam, Jay, McHenry, Leemon, International Journal of Risk & Safety in Medicine. 2016 28[1]:33-43.
  3. ↑ United States v Forest Pharmaceuticals, Plea Agreement, September 15, 2010
  4. ↑ Wagner KD, Robb AS, Findling RL, Jin J, Gutierrez MM, Heydorn WE. A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psych 2004; 161 (6): 1079-1083.
  5. ↑ United States v Forest Pharmaceuticals, Complaint in Intervention p. 17. section 60.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.